<DOC>
	<DOC>NCT01602822</DOC>
	<brief_summary>This study will evaluate how safe and tolerable a combination of taking three-drugs will be for the purpose of preventing HIV transmission after a high-risk sexual contact exposure in HIV uninfected adults.</brief_summary>
	<brief_title>Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV</brief_title>
	<detailed_description>Participants are given a regimen containing TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily,for 28 days.</detailed_description>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Atazanavir Sulfate</mesh_term>
	<mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1. Age of 18 at time of first visit. 2. HIV uninfected on the basis of a negative HIV Rapid Test 3. Possible nonoccupational exposure to HIV1, recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure. 1. Women who are actively trying to become pregnant. 2. Pregnancy and/or Breastfeeding. 3. Known self report of Chronic Hepatitis B infection or prior antiretroviral therapy for hepatitis B. 4. Known intolerance or allergy to study drugs.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>HIV Prevention</keyword>
	<keyword>NPEP</keyword>
	<keyword>PEP</keyword>
</DOC>